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Abstract: Human pathogens impact patient health through a com-
plex interplay with the host, but models to study the role of host
genetics in this process are limited. Human induced pluripotent stem
cells (iPSCs) offer the ability to produce host-speciﬁc differentiated
cells and thus have the potential to transform the study of infectious
disease; however, no iPSC models of infectious disease have been
described. Here we report that hepatocyte-like cells derived from iPS-
Cs support the entire life cycle of hepatitis C virus, including inﬂam-
matory responses to infection, enabling studies of how host genetics
impact viral pathogenesis. 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
HCV infection is a major health problem worldwide since at
least 70% of infections persist and cause chronic hepatitis which
may progress to liver cirrhosis and hepatocellular carcinoma [1].
The lack of robust cell culture and small animal models persists
as stumbling blocks to HCV research. Fortunately, thanks to the
development of cell culture systems that support HCV replication
[2], the entire HCV life cycle is now accessible for investigation.
However, despite its strong advantages, the HCVcc system cannot
completely mimic the events that occur during a natural HCVJournal of Hepatology 20
Keywords: Human induced pluripotent stem cells; Differentiation; Hepatocyte-
like cells; Hepatitis C virus; Host–pathogen interactions.
Received 16 February 2012; received in revised form 20 April 2012; accepted 23 April
2012
⇑Corresponding author. Address: INSERM Unité 972, IFR93 Hospital Bicêtre,
F-94276 Kremlin Bicêtre, France. Tel.: +33 1 4959 1854; fax: +33 1 4959 1959.
E-mail address: karim.si-tayeb@inserm.fr (K. Si-Tayeb).infection in vivo. Recently, HepaRG progenitor cells were shown
to be capable of differentiating into hepatocytes and biliary
epithelial cells, depending on culture conditions [3]. These
progenitors were used as a surrogate for primary human hepato-
cytes [4], and showed to be susceptible to in vitro infection with
serum-derived HCV (genotype 3) and able to support long-term
production of infectious lipoprotein-associated enveloped HCV
particles [5]. Taking these ﬁndings a step further, the model
described by Schwartz, Trehan et al. offers the possibility to study
genetic defects that impact HCV infection of human iPS-derived
hepatocyte-like cells (iHLCs) [6].
The iHLC is an interesting and original cell system for HCV stud-
ies. It results from the efﬁcient generation of highly differentiated
hepatocyte-like cells from iPS cells that display key liver functions
and can integrate into the hepatic parenchyma in vivo [7]. Inhibi-
tion of HNF4a in this systemwas shown to perturb hepatocyte dif-
ferentiation once the endoderm was speciﬁed, mimicking previous
ﬁndings generated from mouse knockout models, suggesting the
usefulness of this model to study hepatocyte development in a
human context [8]. The HLCs and iHLCs co-express alpha fetopro-
tein and albumin, as well as a repertoire of phase-1 and phase-2
drug metabolizing enzymes, which are known to be expressed in
fetal but also adult hepatocytes. To date, studies using HLC were
able to show their application in detoxiﬁcation [9] when differen-
tiated from human ES cells and modeling metabolic inborn genetic
disease (for review, see [10]) when differentiated from human iPS
cells. This is the ﬁrst time that HLCs were described as a model to
study host–pathogen interactions [6].
Schwartz, Trehan et al. reported that (1) iHLCs expressed
known HCV host factors involved in HCV entry (CD81, SRBI,
CLDN1, OCLN); (2) iHLCs supported the entire life cycle of geno-
type 2a HCV reporter virus expressing secreted Gaussia luciferase
(GLuc), as previously described [11], and incubation with antivi-
ral drugs induced a signiﬁcant decrease of viral production.
Culture supernatants at 13 days post infection (dpi) were able
to infect HuH-7.5 cells, which are highly permissive to HCV; (3)
HCV infection induced an antiviral inﬂammatory response by
the increasing mRNA expression of interferon gamma inducible
protein 10 (CXCL-10) and IFN-inducible T cell a chemoattractant
(CXCL-11). These two chemokines, expressed by hepatocytes
during chronic hepatitis C, are in part responsible for the12 vol. 57 j 689–691
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Fig. 1. Hypothetic model for the study of IFN-k responses to HCV infection of patients-derived iHLCs. GLuc-HCV infection of iHLCs derived from patients responding
differently to current treatment could be useful, in association with a combination of GWAS and regional sequencing, for the identiﬁcation of new gene candidates and their
involvement in interferon-k responses. Following iHLCs antiviral activity evaluation from luciferase activity in cell culture supernatants, effects of new gene candidates
could be investigated at the level of IL28B expression (1), JAK–STAT signaling pathway modulation (2), expression of unknown modiﬁer genes (3), and direct or indirect
modulation of interferon stimulating genes (ISG) (4), in order to identify new therapeutic targets.
International Hepatologyrecruitment of inﬂammatory T cells into the liver (for review, see
[12]). TNF-a secretion was detected in cell culture supernatants
from 2 to 14 dpi, and IL-28B/IL-29 only in response to viral
infection at 2 dpi.
Several recent genome wide association studies (GWAS)
report that single nucleotide polymorphisms (SNPs) adjacent to
IL28B (which encodes IFN-k3) predict spontaneous resolution of
HCV infection and outcome of treatment among HCV genotype
1 infected patients [13]. The strongest predictor of sustained viro-
logical response (SVR) is an SNP (rs12979860) and the CC geno-
type, which have SVR rates more than 2-fold higher than when
the T variant is present. The effect of the IL28B haplotype status
on treatment response might be attenuated for genotypes 2690 Journal of Hepatology 201and 3 (for review, see [14]). The mechanisms that mediate the
association between different SNPs and HCV control are poorly
understood. IFN-k activates a transcriptional program resembling
that of IFNa/b in liver cells and inhibits HCV replication in the
JFH1 infection model [15] as well as in human fetal liver cells
[11]. Otherwise, HCVcc induces expression of IFN-k, CXCL-10,
and CXCL-11. Both viral and host factors inﬂuence the level of
gene induction. Concomitant assessment of pretreatment IP-10
or CXCL-10 and IL28B-related SNPs augments the prediction of
the ﬁrst phase decline in HCV RNA and the ﬁnal therapeutic out-
come [16].
A better understanding of HCV/host interactions is urgently
needed in order to develop improved therapies. This study2 vol. 57 j 689–691
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demonstrates that HCVcc infection induces an antiviral inﬂam-
matory response, including chemokines and IL28B. Therefore, as
suggested by the authors, we can speculate that iPSCs generated
from identiﬁed patients with a genetic background that impact
HCV infection could serve as a model for studying the inﬂuence
of innate immunity on such infection, which should considerably
impact our current knowledge on antiviral therapy. In order to
efﬁciently identify new candidate genes and decrease the cost
and time consumption of iPSCs generation, characterization and
differentiation, next generation sequencing technology (NGS)
could now be combined to GWAS as two-phase sampling designs
for patients’ selection (Fig. 1) [17].
Despite the undeniable strength of modeling HCV infection
using cells from diverse genetic backgrounds, further maturation
of iHLCs must be achieved in order to faithfully reﬂect HCV/host
interactions. In addition, it will be important to learn how HCV
isolates representing other HCV genotypes interact with IFN sys-
tems, especially IFN-k (Fig. 1). The study of hepatitis C viral path-
ogenesis with patient-derived iPS cells will open newperspectives
of research opportunities.Conﬂict of interest
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